Floatz logo

Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules

Brain Diseases

Beijing Friendship HospitalPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Brain Diseases cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Donanemab
Eli Lilly and Company
Phase 3B
LEVODOPA
Merck Sharp & Dohme LLC
Phase 2B

View all 43 →

Same molecule, other indications

Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules is also rated in:

basal ganglia disorderDormant
BB
Indicative ·
65 / 100
View asset →
movement disorderDormant
BB
Indicative ·
65 / 100
View asset →
neurodegenerative diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →